Historically, Black patients have been underrepresented in clinical trials testing cancer immunotherapies. While these treatments have led to significant improvements in outcomes for some patients, new research from Michigan Medicine aimed to determine if these benefits also applied to Black patients. Led by Dr. Alex K. Bryant, an assistant professor of radiation oncology at Michigan Medicine, the study examined cancer immunotherapy outcomes in both Black and white patients, analyzing data from more than 26,000 individuals. The researchers call for more studies to explore these racial differences—curious to learn more? Check out the full article for all the insights!
